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either with CABG (106 pts) or DES (105 pts). Decision to treat with CABG
or PCI was dependent on the patient’s and the physisican’s choice. The occur-
rence of major adverse cardiac or cerebrovascular events (MACCE: death, non
fatal myocardial infarction or stroke) and revascularisations was recorded after
one year follow-up. A multivariate logistic regression analysis was performed,
using a propensity score method to take into account potential baseline diffe-
rences between groups.
Results: In-hospital MACCE rates were 5.7% and 3.8% in CABG and PCI
groups, respectively (p=0.748). After, one-year follow-up, rates were respecti-
vely 15.4% and 16.3% (p=0.865). Rates for target vessel revascularisation at
12 months were 1.1% and 15.2% (p<0.001). PCI group was significantly asso-
ciated with older age, dyslipidaemia, history of cancer, high euroscore, ele-
vated creatininemia, single vessel disease, chronic occlusion of left anterior
descending artery and LMCA stenosis ≥70%. The multivariable logistic
regression analysis was adjusted for age, diabetes, left ventricular ejection
fraction, euroscore, and stratified on the propensity score to be treated with
PCI. In the subgroup below median propensity score, the adjusted odds ratio
for one-year MACCE was OR=0.98 (95% confidence interval: 0.17 to 5.67;
p=0.981) whereas OR was 0.20 (0.04 to 0.97; p=0.046) in the subgroup above
median propensity score.
Conclusions: In patients with a high probability to be treated with PCI
(older age, high euroscore, high creatininemia, single vessel disease…), one-
year risk of death was significantly lower in PCI as compared to CABG
treated subjects. No significant difference was found in other cases. 
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Aim: To identify factors associated with change in thrombus pattern in
STEMI patients undergoing primary PCI.
Methods: Thrombi (n=45) were obtained using the Export thromboaspira-
tion device in consecutive STEMI early presenters (<12hours from symptoms
onset) undergoing primary PCI. Ten different areas of each thrombus were
randomly scanned using a Scanning Electronic Microscope (4nm resolution).
High definition pictures (Magnification 3000X) were analysed in a blinded
way by a semi-quantitative and a visual approach to evaluate fibrin and pla-
telet content (in %). The primary endpoint was fibrin and platelet content
according to time delay from symptom onset (SO). All patients were enrolled
in the web-based registry (e-PARIS).
Results: Mean age was 59+/-14 years, 25 (83%) were male, 16 (53%) were
smoker, 12 (40%) had hypertension, 12(40%) dyslipidemia and 7(23%) were
diabetic. 4 patients (13.3%) had pre-hospital cardiac arrest and 25 patients
(83%) had a single vessel disease. All Patients received aspirin, clopidogrel,
enoxaparin or UHF and 25 (83%) received abciximab. Thrombi were com-
posed by 55.9±18% of fibrin (mean±SD), 16.8±18% of platelets, 11.5±9 % of
red cells, 5.2±8.4 % of cholesterol crystal, 1.3±2.0 % of white cells, and
2.8±3.7% mixed cell-fibrin. Median time delay from SO to PCI was (182 min
+/- 235 IQR). There was a stepwise decrease in platelet content with respect
to prolonged time delay from SO to PCI ranging from 25.6±25% in the first
tertile down to 8.7±7% in the third tertile (p=0.09) (fig.). On the other hand,
there was a stepwise increase in fibrin content ranging from 47.8±24% up to
67.3±9% (p=0.04). Analysis of other determinants of clot composition and
relation with myocardial TIMI Blush Grade is pending.
Conclusions: Platelet and fibrin content within the occlusive thrombus of
early STEMI presenters is a fast evolving process. Time delay from symptom
onset is a key determinant of thrombus composition.
Thrombus content in STEMI according ischemic time
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Acute hyperglycemia is associated with adverse outcome after pri-
mary angioplasty for acute myocardial infarction: GLAMI Study
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Hyperglycemia has been shown to be a powerful predictor of worse out-
come after ST segment-elevation myocardial infarction (STEMI).
The aim of this study was to investigate the relation between acute hypergly-
cemia (AHG) and in-hospital outcome after primary angioplasty for STEMI.
Patients and Methods: We prospectively included 250 patients who unde-
rwent revascularization with primary angioplasty for STEMI, Plasma glucose
was measured at hospital admission. Acute hyperglycemia was defined as
plasma glucose of 11 mmol/L (198 mg/dL), regardless of the diabetic status.
Results: Among the 250 patients with STEMI included in the study, 124
(49.6%) patients had acute hyperglycemia. There was no difference among the
two groups with regard to clinical characteristics except for the presence of dia-
betes (58%vs 7.1%, p<0.001), hypertension (21.4% vs 38.7%, p=0.002) and
hyperlipidemia (4.8% vs 14.5%, p=0.007. At admission, patients with AHG
were more likely to have tachycardia (26.6 % vs 14.3%, p=0.012) and to present
heart failure (24.2% vs 12.7%, p=0.01). The admission TIMI flow was similar
in the two groups. TIMI 3 flow postprocedure was more common in patients
without AHG (89.7% vs 75%, p=0.002). The in-hospital mortality rate was
significantly higher in patients with AHG than in patients without (22.6% vs
4.8%, p <0.001) . In multivariate analysis, independently of other determinants
of death ( age, risk factors, location of STEMI, infarct size, incomplete resolu-
tion of ST-segment and angiographic success), acute hyperglycemia was a pre-
dictor of in-hospital mortality ( OR: 3.14; 95% IC, 1.5-6.5; p=0.0001).
Conclusion: Acute hyperglycemia in patients with STEMI was an impor-
tant predictor of mortality, this suggest the usefulness of evaluating early gly-
cemic control in the setting of reperfusion for acute myocardial infarction.
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Benefit of Drug Eluting Stents over Bare Metal Stents after Rotatio-
nal Atherectomy. A propensity score adjusted comparison in revascu-
larization, mortality and MACE.
Francois Schiele, Kais Mrabet, Nicolas Meneveau, Marie-France Seronde,
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CHU Besancon, Cardiologie, Besancon, France
Rationale: Rotational atherectomy makes possible to attempt small and
calcified arteries while Drug Eluting Stents (DES) properties may reduce the
restenosis process, rendering this combination attractive in selected cases. We
compared 1year clinical outcome after rotational atherectomy following by
either DES or Bare Metal Stents (BMS) implantation.
Methods: Single centre registry including all consecutive cases of rota-
tional atherectomy use. Clinical follow-up was obtained in all patients. Pro-
pensity score for being treated with a DES was calculated using 18 clinical,
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angiographic and procedural variables. Comparison was adjusted on 4 strata of
the propensity score.
Results: Between 2002 and 2008, 223 patients were treated: 114 with BMS
and 110 with DES. Most of the patients with BMS between 2002 and 2004
and later with DES. No significant difference was observed in clinical charac-
teristics between groups: age 70 years, reference diameter 2.40±0.60mm,
lesion length 10±9mm. Two cases of coronary perforation occurred, 7 lesion
failure, and 12 transcient no-reflow. The use of GP2b3a inhibitors was similar
in both groups, but, compared with BMS, patients in the DES group had
longer duration of combination of aspirin and Clopidogrel. At one year, signi-
ficantly lower rates of vessel revascularisation (2% vs 12%, p=0.005), of all
cause mortality (5% vs 14%, p=0.05) and of MACE (10% vs 22%, p=0.02)
were observed in the DES than in the BMS group. Adjustment on the strata of
the propensity score did not change significantly these results (figure).
Conclusions: Despite propensity score adjusted, this comparison has limita-
tions. After rotational atherectomy we observed clear benefit for DES implanta-
tion over BMS on vessel revascularisation, mortality and MACE rates.
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Background: Numerous recent studies showed that about 4 to 30% of patients
treated with conventional doses of clopidogrel do not display adequate antiplatelet
response and then the concept of clopidogrel resistance has arisen. Recently, a
number of observations have indicated that patients with diabetes mellitus (DM)
exhibit persistent platelet activation and low response after antiplatelet therapy.
Objective: The purpose of this study was to establish the prevalence and
the predictive factors of the resistance to clopidogrel in a coronary artery
disease population, using ex vivo measure of platelet aggregation: the cone
and platelet analyzer.
Methods: The population of this prospective study was comprised of 105
patients with acute coronary syndrome. Mean age was 57.8 ± 10.8 years, 81.9
% were males, 36,5% patients had history of hypertension, 54,3% patients were
diabetic. Patients were given a loading dose of 300-600 mg followed by a main-
tenance dose of 75 mg on top of a maintenance dose of aspirin ranging from 125
mg to 250 mg. Platelet aggregation was assessed using the Impact R (Diamed®).
The degree of platelet adherence was evaluated as a percentage of surface cove-
rage (SC). Residual platelet reactivity was defined as a SC ≤ 2.8 %.
Results: The mean surface coverage was of 7.78 + 4.29 %. We found that
17.1 % of our population was clopidogrel resistant. By univariate analysis
female sex and diabetes were associated with an increased incidence of clopi-
dogrel resistance, nevertheless, by multivariate analysis, diabetes was the only
independent predictive factor, (OR=3.5, IC 952[1.1-11.4]; P=0.0039). The pre-
valence of clopidogrel resistance was higher in diabetic patients compared to
non diabetics (24.6% vs 8.3%; p=0.02) respectively. This prevalence was
greater in diabetic patients treated by insulin (30%). Concomitant medication
did not influence the incidence of clopidogrel resistance in particular the use
of Omeprazol and Atorvastatin.
Conclusions: Diabetic patients do not respond well to the available antipla-
telet regimen when compared with similar patients without DM. The clinical
implications of these findings are unknown but are potentially important.
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Background: Gamma’ fibrinogen (γ’Fg) is a Fg isoform that constitutes about
15% of total plasma Fg and contains an additional binding site for factor XIII and
for IIa forming clots that are resistant to fibrinolysis in vitro. Little is known about
γ’Fg in the pathophysiology of Acute Coronary Syndrome (ACS) patients.
Aim: To compare γ’Fg level and the relation with fibrin clot physical pro-
perties in a young post-MI patients matched for age and gender and age with
healthy controls.
Method: γ’Fg was measured in duplicates in 260 young post-MI patients
and n=260 controls. Maximum fibrin elastic modulus (EM in dyne/cm2), a
measure of clot stiffness (G’) and Clot Lysis Time (CLT in sec) a measure of
fibrinolysis rate were measured in all subject.
Results: Patients produced stiffer plasma fibrin with increased EM
(24.4±15.9 vs 13.5±5.9 kdynes/cm2 ; p<0.0001) with reduced fibrinolysis
speed (1038±797 vs 595±416 sec; p<0.0001) in comparison with controls.
γ’Fg concentration was significantly higher in patients compared to control
(Figure 1) (p=0.037). However the ratio of γ’Fg over total Fg concentration
(% of γ’Fg) was similar in both groups (3.7± 2% vs 3.5± 2.7% in controls;
p=0.49). In patients there was a stepwise increase in clot stiffness (EM) with ter-
tile of γ’Fg concentration (T1=13.7±7 T2=19.8±14 T3=23.7±16 in kdynes/cm2)
with a similar effect on hypofibrinolysis (CLT) (T1=675±550 T2=829±680 T3=
940±750) (p<0.0001 for both).
Conclusion: γ’Fg concentration was found to be significantly higher in
young post-MI patients as compared to healthy controls matched for age and
gender and may account for the great differences in fibrin clot physical pro-
perties between patients and controls, an independent correlate of premature
coronary artery disease.
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